A股異動 | 生益科技(600183.SH)漲逾4% 預計三季度扣非歸母淨利潤同比增77%至85%
格隆匯10月19日丨生益科技(600183.SH)漲逾4%,報22.7元,總市值524億元。公司昨日盤後披露2021 年前三季度業績預增公吿,公吿顯示前三季度預計實現歸母淨利23.3~23.6 億元( 同比增79%~81% ), 扣非歸母21.2~21.5 億元(同比增72%~75%),對應21Q3 單季度歸母淨利9.2~9.5 億元(同比增93%~99%,環比增5.7%~9.2%),扣非歸母7.2~7.5 億元(同比增77%~85%)。21Q3 單季度非經常性項目主要來自於陝西生益老厂部分土地使用權被政府收儲,資產處置收益貢獻1.8 億。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.